179 related articles for article (PubMed ID: 31500446)
21. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
22. Systemic management strategies for metastatic soft tissue sarcoma.
Movva S; Verschraegen C
Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
[TBL] [Abstract][Full Text] [Related]
23. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
[TBL] [Abstract][Full Text] [Related]
24. Systemic Treatment for Adults with Synovial Sarcoma.
Desar IME; Fleuren EDG; van der Graaf WTA
Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Schmoll HJ; Lindner LH; Reichardt P; Heißner K; Kopp HG; Kessler T; Mayer-Steinacker R; Rüssel J; Egerer G; Crysandt M; Kasper B; Niederwieser D; Kunitz A; Eigendorff E; Petersen I; Steighardt J; Cygon F; Meinert F; Stein A
JAMA Oncol; 2021 Feb; 7(2):255-262. PubMed ID: 33355646
[TBL] [Abstract][Full Text] [Related]
26. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
27. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Schöffski P; Cornillie J; Wozniak A; Li H; Hompes D
Oncol Res Treat; 2014; 37(6):355-62. PubMed ID: 24903768
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
29. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Grignani G; Martín-Broto J; Schuler M; Reichardt P
Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
31. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
[TBL] [Abstract][Full Text] [Related]
33. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
34. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
[TBL] [Abstract][Full Text] [Related]
35. Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Assi T; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Curr Treat Options Oncol; 2023 Nov; 24(11):1598-1613. PubMed ID: 37843627
[TBL] [Abstract][Full Text] [Related]
36. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
Pautier P; Penel N; Ray-Coquard I; Italiano A; Bompas E; Delcambre C; Bay JO; Bertucci F; Delaye J; Chevreau C; Cupissol D; Bozec L; Eymard JC; Saada E; Isambert N; Guillemet C; Rios M; Piperno-Neumann S; Chenuc G; Duffaud F
Eur J Cancer; 2020 Jan; 125():31-37. PubMed ID: 31835236
[TBL] [Abstract][Full Text] [Related]
37. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Tanaka K; Ozaki T
Jpn J Clin Oncol; 2022 May; 52(6):526-530. PubMed ID: 35292817
[TBL] [Abstract][Full Text] [Related]
38. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
Chamberlain F; Benson C; Thway K; Huang P; Jones RL; Gennatas S
Future Oncol; 2021 Jul; 17(20):2659-2670. PubMed ID: 33880964
[TBL] [Abstract][Full Text] [Related]
39. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.
Casali PG
Ann Oncol; 2012 Sep; 23 Suppl 10():x167-9. PubMed ID: 22987955
[TBL] [Abstract][Full Text] [Related]
40. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
